Navigation Links
John H. Flood III Named as CEO of Flagship Global Health, Inc.
Date:11/21/2007

NEW YORK, Nov. 21 /PRNewswire-FirstCall/ -- Flagship Global Health, Inc. ("Flagship") (OTC Bulletin Board: FGHH) announces the promotion of John Flood as its new Chief Executive Officer. Co-founder Fred Nazem remains Chairman of the Board of Flagship. Mr. Flood has been President of Flagship and joined the specialty healthcare advocacy company in 2004. He will be responsible for the entire affairs of Flagship while Mr. Nazem will focus on the strategic direction of the Company.

"Having achieved so much of my dream as a founder of the Company and now as a recognized leader in the membership-based specialty healthcare advocacy space, I've concluded it is time for me to pass the CEO torch to John who will be responsible for all the day to day management of the Company." said Mr. Nazem. " As Chairman, I will focus my time and energy on the strategic growth of Flagship in order to ensure the continuation of its leadership position in the industry," he continued. The appointment of John Flood as the new Chief Executive Officer of Flagship is effective immediately.

"Fred and I have worked closely and very effectively together since the early days of the Company. With so many great opportunities facing us every day as a result of the high marks we have been getting from our members and our 4,000 or so top physicians, I am excited about concentrating my efforts as the new CEO on optimizing our entire operations so that we can properly capitalize on some of these opportunities," remarked Mr. Flood.

Mr. Flood joined Flagship Global Health in 2004. Before joining Flagship he was the managing partner of Flood Donohue Johnston & McShane, from 1994 to 2004. From 1984 to 1994, he worked for NFL Properties, the centralized marketing company of the National Football League, where he served as company President and helped the company grow to over one billion dollars in retail sales. Mr. Flood received his AB in Psychology from Harvard University and his JD
'/>"/>

SOURCE Flagship Global Health, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. UNICEF Readies to Assist Mexican Flood Victims
2. Red Cross President Visits Flooded Regions in Mexico
3. Keith Taft Named General Manager of UltraTape Industries
4. Summa Health Systems Akron City Hospital Named Leapfrog Top Hospital for 2007
5. Heartline(R) Fitness Systems Named to Inc. Magazines Inaugural List of the 5000 Fastest Growing Private Companies in U.S....
6. Allscripts Named to FORTUNE 100 Fastest-Growing Companies List
7. Boston Micromachines Multi-DM Named One of the Years Most Innovative Products
8. Karen Vigil Named Senior Vice President and Chief Executive Officer, Blue Shield of Californias Individual, Small Group, and Government Business Unit
9. New Director of Nursing Practice Named for Nurses Association
10. Instrumentation Laboratory Named Top of Class by Respiratory Care Managers
11. Meeting Expectations Named to First Annual CMI 25 List by Corporate Meetings & Incentives Magazine

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...constructive Surgery...In Brief is distributed mon...current journal news from the American Society of ...s highlighted here, or to arrange an interview wit...ions at (847) 228-9900 or media@plasticsurgery.org...2009 -- Yes, Plastic Surgeons Have Plastic Surgery...
(Date:11/23/2009)...-ThousandsofpeoplewithiPhoneshavealreadydownloaded...tesbettermanagetheirdiseasethroughabetterunderstan...managetheirbloodsugar.Nowit,sbecomeeveneasierthrou... RocheDiabetesCare,themakeroftheACCU-CHEK®lin...partneredwithMYLEstoneHealth,thedeveloperofGlucose...
(Date:11/23/2009)..., Reportlinker.comannouncesthatanewmarketresearch...w.reportlinker.com/p0165298/Childrens-Food-and-Dri...novation-2nd-Edition.html#utm_source=prnewswire&am..., Despitethegrowingattentionbeingpaidtotheworld,sa...groupthatcannotbeoverlooked.Childrenagedbetween5an...
(Date:11/23/2009)...G.Schwade,M.D.announcesthenewlyenhancedCyberKnifee...enterofMiami,( www.cyberknifemiami.com ). ,, ...dintensedoseofradiationthatkillscancercellswithnoi...lastfrom30minutestoonehour,andisusuallycompletedin...CenterintheSoutheasternU.S.,theMiamifacilityhasled...
(Date:11/23/2009)...rtlinker.comannouncesthatanewmarketresearchreporti...MarketTrends ,, http://www.reportlinker.com/...tm_source=prnewswire&utm_medium=pr&utm_cam...suchasSARS,outbreakoffluandbioterrorismhavefurther...ventingthespreadofinfections.Allthesefactorshaveco...
Breaking Medicine News(10 mins):Health News:Plastic and Reconstructive Surgery...In Brief 2Health News:Plastic and Reconstructive Surgery...In Brief 3Health News:ACCU-CHEK(R) Partners With MYLEstone Health to Enhance iPhone App Glucose Buddy and Web Site glucosebuddy.com 2Health News:ACCU-CHEK(R) Partners With MYLEstone Health to Enhance iPhone App Glucose Buddy and Web Site glucosebuddy.com 3Health News:Reportlinker Adds Children's Food and Drinks in Europe - A Guide to Markets, Products and Innovation 2nd Edition 2Health News:Reportlinker Adds Children's Food and Drinks in Europe - A Guide to Markets, Products and Innovation 2nd Edition 3Health News:Reportlinker Adds Children's Food and Drinks in Europe - A Guide to Markets, Products and Innovation 2nd Edition 4Health News:Reportlinker Adds Children's Food and Drinks in Europe - A Guide to Markets, Products and Innovation 2nd Edition 5Health News:Reportlinker Adds Children's Food and Drinks in Europe - A Guide to Markets, Products and Innovation 2nd Edition 6Health News:Reportlinker Adds Children's Food and Drinks in Europe - A Guide to Markets, Products and Innovation 2nd Edition 7Health News:Reportlinker Adds Hand Sanitizers - US Market Trends 2Health News:Reportlinker Adds Hand Sanitizers - US Market Trends 3Health News:Reportlinker Adds Hand Sanitizers - US Market Trends 4
...ishing a common stomach-dwelling bacterium makes t... Many people would benefit from chronic usage// of...ke aspirin and diclofenac. Not only do these drugs... drawback. They may lead to stomach bleeding and u...
...rts have long thought depression could be bad for ...erous it can be. Brenda Penninx, a US gerentologis...e of 55//- both with and without heart disease- fo...eart disease as were patients who weren't depresse...
...dark winter months motivate binge eating in certai...ersity of Irvine have been looking at the factors ...rders, where binge eating is a significant symptom...different from the comfort eating that many of us ...
...cing body temperature by just a few degrees minimi...hen the heart suddenly stops - cardiac arrest - th...d of oxygen. //Even if the person survives, they r... it after a cardiac arrest. Doctors in Vienn...
...do you know when someone who talks about suicide w... difficulty deciding which depressed patients need... they have found a way to assess risk: a blood tes... the final step. So says psychiatrist William Cory...
...unfrozen ready-to-eat meals could lead to the resu...d. Advances in freezing have made botulism a rare ...cientists, a new generation of ready-to-eat foods/...oking of foods, some botulism poisoning in recent ...
Other Medicine News:
(Date:11/23/2009)..., NOVATO,Calif.,Nov.23/PRNewswire-FirstCall/-...(Nasdaq: RPTP ),todayannouncedresultsfromaPhase2bc...inebitartrate("DRCysteamine")inpatientswithnephrop...theUniversityofCalifornia,SanDiego("UCSD")GeneralC...,pharmacokineticsandpharmacodynamicsofasingledoseo...
(Date:11/23/2009)..., EMERYVILLE,Calif.,Nov.23/PRNewswire-FirstCa... )("NTI")announcedtodaythatitsboardofdirectorshasd...monstock,whichwillbepaidonDecember9,2009tostockhol...xtraordinarydividendfollowsstockholderapprovalofth...ionanddissolutionandanearlierextraordinarydividend...
(Date:11/20/2009)..., , WAYNE, Pa., Nov. 20 /PRNewswire-FirstCal...announced the results for its fiscal first quarter...uarter of fiscal 2010, product revenue decreased a...ng the three-month period ended September 30, 2009... The Company reported the decreased net revenue of...
Breaking Medicine Technology:Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 2Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 5Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share 2Escalon(R) Reports First Quarter Fiscal 2010 Results 2Escalon(R) Reports First Quarter Fiscal 2010 Results 3Escalon(R) Reports First Quarter Fiscal 2010 Results 4Escalon(R) Reports First Quarter Fiscal 2010 Results 5Escalon(R) Reports First Quarter Fiscal 2010 Results 6Escalon(R) Reports First Quarter Fiscal 2010 Results 7Reminder program dramatically increases mammography rates Kaiser Permanente study finds 51578 1Reminder program dramatically increases mammography rates Kaiser Permanente study finds 51578 2Reminder program dramatically increases mammography rates Kaiser Permanente study finds 51578 3FAIR CEO Blasts Kaiser Foundation 26amp 3B Public Agenda HIV AIDS Study Results as 26quot 3BAbsolute Nonsense 26quot 3B 51573 1FAIR CEO Blasts Kaiser Foundation 26amp 3B Public Agenda HIV AIDS Study Results as 26quot 3BAbsolute Nonsense 26quot 3B 51573 2FAIR CEO Blasts Kaiser Foundation 26amp 3B Public Agenda HIV AIDS Study Results as 26quot 3BAbsolute Nonsense 26quot 3B 51573 3FAIR CEO Blasts Kaiser Foundation 26amp 3B Public Agenda HIV AIDS Study Results as 26quot 3BAbsolute Nonsense 26quot 3B 51573 4Eliminating polio requires global coordinated effort Health Affairs article highlights risks rewards of eradication 51569 1Eliminating polio requires global coordinated effort Health Affairs article highlights risks rewards of eradication 51569 2Eliminating polio requires global coordinated effort Health Affairs article highlights risks rewards of eradication 51569 3Eliminating polio requires global coordinated effort Health Affairs article highlights risks rewards of eradication 51569 4Eliminating polio requires global coordinated effort Health Affairs article highlights risks rewards of eradication 51569 5
...pr 16, 2007 - Amgen,(Nasdaq:AMGN) today presented ...bo-controlled Phase 3 study evaluating the,efficac...the,treatment of anemia in patients with active ca...the 103 study"). Aranesp is not,approved for use b... were presented in an oral session at the 2007 Ame...
...nt not met; plausibly,confounded by survival benef...K, April 16, 2007 /PRNewswire-FirstCall/ -- ImClon...mpany today,announced detailed results from the EP...Phase III trial - comparing ERBITUX(R),(Cetuximab)...ith,metastatic colorectal cancer (mCRC) who failed...
Other Medicine Technology:Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 2Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 5Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 6Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 2Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 4Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 5Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 6Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 8Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 9
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
Keeler Sport Frames
Medicine Products: